View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
June 8, 2021

FDA lifts clinical hold on bluebird bio’s gene therapy trials

bluebird bio can now resume Phase I/II HGB-206, Phase III HGB-210, Northstar-2 and Northstar-3 trials.

The US Food and Drug Administration (FDA) has lifted the clinical hold placed on bluebird bio’s gene therapy trials in February this year.

This allows the company to restart the Phase I/II HGB-206 and Phase III HGB-210 trials of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) in adult and paediatric SCD patients.

In addition, the FDA lifted the clinical hold on the Phase III Northstar-2 (HGB-207) and Northstar-3 (HGB-212) trials of betibeglogene autotemcel gene therapy (beti-cel) in adult, adolescent, and paediatric subjects with transfusion-dependent β-thalassemia (TDT).

bluebird bio severe genetic diseases president Andrew Obenshain said: “Over the past four months, we have gained deeper knowledge and understanding of the pathophysiology of sickle cell disease that will allow us to better serve patients and the broader community.

“We look forward to resuming our clinical programmes and continuing to advance toward major regulatory submissions for sickle cell disease and β-thalassemia.”

The company temporarily stopped the trials in February after two patients in the Phase I/II HGB-206 trial developed blood cancer following LentiGlobin gene therapy treatment.

One patient developed a suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukaemia (AML), while the other developed SUSAR of myelodysplastic syndrome (MDS).

bluebird bio also suspended the marketing of betibeglogene autotemcel as it uses the same BB305 lentiviral vector as LentiGlobin.

In March, a bluebird assessment found that the SUSAR of AML in LentiGlobin for SCD is ‘very unlikely’ to be associated with the BB305 lentiviral vector.

No hematologic malignancy cases were reported in patients treated with beti-cel, the company added.

In April, further assessment showed that the trial participant who was diagnosed with SUSAR of MDS had actually developed transfusion-dependent anaemia, according to the trial investigator. Based on this, the company reported a revised diagnosis for the MDS case.

bluebird bio is currently collaborating with trial investigators and sites to restart all study activities.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena